APA (7th ed.) Citation

Jessica M. Illenberger, Francisco J. Flores-Ramirez, Alessandra Matzeu, Barbara J. Mason, & Rémi Martin-Fardon. (2023). Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Jessica M. Illenberger, Francisco J. Flores-Ramirez, Alessandra Matzeu, Barbara J. Mason, and Rémi Martin-Fardon. Suvorexant, an FDA-approved Dual Orexin Receptor Antagonist, Reduces Oxycodone Self-administration and Conditioned Reinstatement in Male and Female Rats. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Jessica M. Illenberger, et al. Suvorexant, an FDA-approved Dual Orexin Receptor Antagonist, Reduces Oxycodone Self-administration and Conditioned Reinstatement in Male and Female Rats. Frontiers Media S.A., 2023.